abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
May 22, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Low Loss Fill Process at Berkshire Sterile Manufacturing
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
May 18, 2023 13:00 ET | Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...
SPR Therapeutics LOGO 361 TM.jpg
Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
May 17, 2023 10:16 ET | SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
revive-therapeutics.png
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 12, 2023 07:00 ET | Revive Therapeutics Ltd.
TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
May 09, 2023 03:30 ET | AKAMPION
Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth Leipzig,...
Axiom-22 Anniversary Logo - Transparent.png
Axiom Exhibiting at Clinical Operations in Oncology Trials West Coast 2023
April 25, 2023 13:13 ET | Axiom Real-Time Metrics Inc
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations,...
Chart 1
Lifeist’s Mikra Announces Successful Study Results for CELLF
April 13, 2023 07:06 ET | Lifeist Wellness Inc.
TORONTO, April 13, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCQB: LFSWF), a health-tech company that leverages advancements in...
revive-therapeutics.png
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
March 28, 2023 07:00 ET | Revive Therapeutics Ltd.
TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
CytoSorbents ISICEM 2023 Picture
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
March 22, 2023 08:09 ET | CytoSorbents
PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
revive-therapeutics.png
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
March 20, 2023 08:28 ET | Revive Therapeutics Ltd.
TORONTO, March 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...